8-K/A: Strata adds Keystone financials, pro formas

Strata Critical Medical filed audited Keystone results and pro forma statements reflecting the Keystone acquisition and the sale of its Passenger business to Joby Aviation’s subsidiary, detailing consideration, contingencies, and combined performance.

Summary

• Included audited 2024 and unaudited June 30, 2025 financials for Keystone Perfusion Services, plus pro forma results reflecting the Keystone acquisition and the sale of the Passenger business to Joby Aviation’s subsidiary.
• Keystone 2024 results: revenue $42.88M, gross profit $8.78M (~20.5% margin), operating income $3.30M, net income $2.97M, operating cash flow $3.57M; year-end total assets $16.92M and total debt $4.43M.
• Keystone 1H 2025 growth: revenue $34.36M (vs. $18.43M 1H24), net income $3.14M; Q2 2025 revenue $18.67M and net income $1.79M.
• Acquisition consideration: $110.0M cash (including $65.6M to seller and $44.3M to third parties) and 3,434,609 shares, with 1,717,303 shares held in escrow; purchase price subject to up to $12.4M adjustment based on 2025 Adjusted EBITDA; additional earn-outs up to $23.0M (2026–2028).
• Passenger business sale (Aug 29, 2025): received 5,325,585 Joby Aviation shares valued ~$75.4M at closing; subsequently sold for net proceeds of $70.2M; potential additional $35.0M contingent consideration plus up to $10.0M indemnity holdback releases (fair values estimated at $27.8M and $8.4M).
• Pro forma combined revenue: $189.17M (2024) and $176.24M (9M25); pro forma 2024 net loss of $17.69M; pro forma 9M25 operating loss of $53.38M (Keystone historical includes ~$38.3M pre-close transaction-related costs).
• Intangibles recognized for Keystone: customer relationships ($32.8M, 10-yr life), trademarks ($8.8M, 10-yr life), developed technology ($1.0M, 3-yr life); incremental amortization of $4.49M (2024) and $3.18M (9M25).
• Keystone financing: $785k SBA equipment loan at 9% (outstanding $676k at 12/31/24; $630k at 6/30/25) and a $4.0M PS Bank revolving LOC at Prime + 0.5% (8% at 12/31/24; $3.76M outstanding at 12/31/24; $2.29M at 6/30/25); no financial covenants disclosed.
• Deloitte & Touche LLP provided an unqualified audit opinion on Keystone’s 2024 financial statements and consented to incorporation by reference in Strata’s existing S-3 and S-8 registration statements.

Sentiment

Score: 6

Explanation: Positive shift to a profitable, growing medical services business and monetization of the Passenger segment are offset by pro forma losses, higher amortization, and contingent outcomes.

Positives

• Keystone is profitable and growing: 2024 net income $2.97M; 1H25 net income $3.14M with strong revenue growth (1H25 revenue $34.36M vs. $18.43M 1H24).
• Healthy cash generation at Keystone in 2024 (operating cash flow $3.57M) despite increased capex ($3.25M).
• Sale of Passenger business produced $70.2M net cash from share sales, with potential for up to $45.0M additional value (earn-out/retention and holdbacks).
• No financial covenants on Keystone SBA loan or LOC, providing flexibility.
• Customer concentration manageable: no single customer >10% of A/R at 12/31/24; only one customer at 10% of 2024 revenue.
• Clean audit opinion for Keystone 2024 financials; auditor consent obtained for S-3 and S-8.

Negatives

• Pro forma combined operations remain loss-making: 2024 net loss of $17.69M; 9M25 pro forma operating loss of $53.38M.
• Keystone incurred substantial pre-close transaction costs and change-in-control bonuses (~$38.3M), depressing 9M25 Keystone historical results included in pro forma.
• Higher ongoing amortization from acquired intangibles ($4.49M in 2024 pro forma; $3.18M in 9M25) will pressure earnings.
• Working capital intensity: large accounts receivable balances ($8.56M at 12/31/24; $10.70M at 6/30/25) and growing inventory.
• Reliance on short-term LOC (demand repayable) and variable interest rates (Prime + 0.5%).

Risks

• Competition from national and regional perfusion and organ recovery service providers could pressure pricing and growth.
• Changes in healthcare reimbursement and hospital spending may adversely affect service demand and margins.
• Dependence on regulatory and accreditation compliance; adverse regulatory changes could impact operations.
• Loss or changes in relationships with significant customers could adversely affect results.
• Dependence on key clinical and management personnel; turnover could disrupt operations.
• Technological advances in cardiac surgery, organ preservation, or clinical practices could reduce demand for current services.
• Acquisition purchase price adjustment of up to $12.4M based on 2025 Adjusted EBITDA and contingent earn-outs up to $23.0M (2026–2028) introduce outcome variability.
• 1,717,303 shares issued at closing are held in escrow and are contingently returnable based on Keystone’s 2025 Adjusted EBITDA.
• Contingent consideration from the Passenger business sale (up to $35.0M earn-out/retention and $10.0M indemnity holdbacks) may not be realized.

Future Outlook

Focus shifts to higher-margin medical services following the Passenger business divestiture, with performance tied to Keystone’s growth and integration. Final Keystone purchase price will adjust by up to $12.4M based on 2025 Adjusted EBITDA (to be settled by March 2026), while additional earn-outs (2026–2028) and potential contingent proceeds from the Passenger sale could affect future cash flows. Management cautions that pro forma results are informational and not predictive of future performance.

Management Comments

• Provided Keystone historical financial statements and unaudited pro forma condensed combined financial information required by Regulation S-X in connection with the Keystone acquisition and the Passenger business sale.
• Stated that the pro forma financial information is presented for informational purposes only and is not necessarily indicative of future results.
• Clarified that Keystone P.C. reorganized into Keystone immediately prior to closing, and the historical financials presented represent the predecessor operations.
• Noted that 1,717,303 shares issued as part of the Keystone consideration are held in escrow and are contingently returnable based on Keystone’s 2025 Adjusted EBITDA.

Industry Context

The transaction solidifies a pivot toward specialized transplant-related services (perfusion, organ recovery, ECMO support), areas benefiting from rising transplant volumes and hospital outsourcing trends. This positions the company alongside specialized healthcare services providers and adjacent organ-preservation platforms (e.g., TransMedics in organ transport/preservation) rather than aviation/passenger mobility businesses.

Comparison to Industry Standards

• Keystone’s 2024 gross margin (~20.5%) aligns with labor- and equipment-intensive specialty healthcare services, lower than asset-light staffing peers (e.g., AMN Healthcare and Cross Country Healthcare gross margins typically ~30–35%) and far below product-centric transplant technology vendors (e.g., TransMedics gross margins >70%).
• Pro forma operating losses in 2024 and 9M25 compare unfavorably to profitable specialty healthcare peers; however, Keystone standalone profitability and growth suggest integration and amortization impacts are the primary drivers of consolidated losses.
• Working-capital intensity (notably A/R) is consistent with hospital-facing service models where billing cycles extend collections relative to retail or subscription models.

Stakeholder Impact

• Shareholders: Strategic pivot toward healthcare services; dilution from 3,434,609 shares issued (with 1,717,303 held in escrow) for the Keystone acquisition.
• Employees: Keystone management received $35.9M in transaction bonuses (paid by the buyer), and profit-sharing plans continue to accrue.
• Customers: Continuity and expansion of perfusion and organ recovery services across U.S. hospitals and transplant centers.
• Creditors: Reduced Keystone debt balances by mid-2025; continued access to a $4.0M LOC at variable rates.

Next Steps

• Finalize Keystone purchase price adjustment based on 2025 Adjusted EBITDA by March 2026.
• Pursue contingent consideration from the Passenger business sale upon meeting 12- and 18-month targets and potential indemnity holdback releases.
• Integrate Keystone operations and manage amortization of acquired intangibles over their useful lives.

Key Dates

Recommendation

The filing confirms Keystone’s profitability and growth and documents substantial cash generated from the Passenger business divestiture, but consolidated pro forma losses, increased non-cash amortization, and multiple contingent outcomes (purchase price adjustment, earn-outs, and sale contingencies) introduce uncertainty. A hold is warranted pending integration progress, clarity on 2025 Adjusted EBITDA true-up, and visibility into synergy realization.

Keywords

Strata Critical Medical, Keystone Perfusion Services, organ recovery, perfusion, ECMO, transplant services, acquisition, pro forma financials, Joby Aviation, Passenger business sale, earn-out, escrow shares, intangible amortization, SBA loan, line of credit